Every 10-Q that Whitehawk Therapeutics, Inc. (WHWK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow WHWK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WHWK filings page.
Whitehawk Therapeutics, Inc. reported a net loss of $16.6 million for the quarter and $38.8 million for the six months ended June 30, 2026, with no product revenue following the March 2025 divestiture of its FYARRO business. Operating expenses for the first half totaled $41.6 million, driven mainly by $30.1 million in research and development and $11.5 million in selling, general and administrative costs.
Other income for the first half of 2026 was $2.8 million, primarily interest on the company’s investment portfolio. After the FYARRO sale, Whitehawk is focused on a portfolio of three next-generation antibody drug conjugates licensed from WuXi Biologics, with two clinical and one preclinical-stage candidates.
Liquidity is strong: at June 30, 2026, cash, cash equivalents and short-term investments were $190.0 million, total liabilities were $11.1 million, and stockholders’ equity was $182.9 million. Net cash used in operating activities was $36.7 million for the first half, largely offset by $81.8 million in net proceeds from a May 2026 PIPE financing. Management states existing funds are expected to support operations into the second half of 2028.
Whitehawk Therapeutics reported first-quarter 2026 results with a net loss of $22.2 million, reflecting its transition to a pure clinical-stage antibody drug conjugate (ADC) company after selling its FYARRO business in 2025.
The company generated no revenue in the quarter versus $7.1 million a year earlier, when results included FYARRO sales and an $87.4 million gain on that divestiture. Operating expenses were $23.5 million, driven mainly by $17.2 million in research and development for its three ADC programs. Cash, cash equivalents and short-term investments totaled $123.0 million at March 31, 2026, and management believes existing resources can fund planned operations into 2028.
Whitehawk Therapeutics reported Q3 2025 results marked by its transition to a preclinical ADC portfolio. The quarter showed $0 revenue and a net loss of $17.7 million, driven by $19.5 million in operating expenses and offset by $1.9 million in interest income. For the nine months, the company recorded net income of $2.7 million, primarily due to an $87.3 million gain on the FYARRO business sale.
Liquidity strengthened with cash, cash equivalents and short‑term investments of $162.6 million as of September 30, 2025. The company paid $38.0 million plus 6% VAT in April 2025 under its WuXi Biologics license covering three ADCs (MUC16, PTK7, SEZ6). The FYARRO divestiture closed for $102.4 million on March 25, 2025, and a March 2025 private placement added $94.4 million net. An ATM of up to $75.0 million remains unused. Shares outstanding were 47,128,362 as of November 4, 2025.
In its first quarter post-divestiture, Whitehawk Therapeutics (WHWK) filed a Q2 2025 10-Q showing a markedly stronger balance sheet and a shift to pre-clinical R&D.
Liquidity: Cash, cash equivalents and short-term investments rose to $177.2 M from $47.2 M at YE-24, funded by the $102.4 M sale of FYARRO (closed 25 Mar 25) and a $100 M PIPE (21.6 M shares & 20.1 M pre-funded warrants at $2.40).
Operations: With FYARRO gone, Q2 revenue fell to $0 (vs $6.2 M). R&D expense jumped to $48.8 M (Q2 24: $13.1 M) after paying the remaining $38 M WuXi license fee for three antibody-drug conjugate (ADC) programs. SG&A declined 25 % YoY to $5.9 M. Net loss widened to $52.6 M (-$0.76/sh).
Six-month view: An $87.4 M gain on the FYARRO sale produced $20.4 M net income for 1H 25, yet operating cash burn reached $64.8 M.
- Total assets: $180.8 M; liabilities: $8.8 M; no debt.
- Equity climbed to $172.1 M and shares outstanding to 47.1 M (8 Aug 25).
- Outstanding dilution: 22.1 M pre-funded warrants & 7.6 M options.
Outlook: Management believes current cash funds ≥12 months of accelerated ADC development; future value creation now hinges on advancing these pre-clinical candidates into the clinic.